Related Experiment Video
Updated: Nov 1, 2025

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015
A comparison of COVID-19 inpatients by HIV status
Sarah Flannery1, Rebecca Schwartz2, Rehana Rasul3
1Division of Infectious Diseases, Department of Medicine, 232890Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.
Insights
People living with HIV (PLWH) hospitalized with COVID-19 had similar outcomes to HIV-negative patients. However, PLWH with low CD4 counts or off HIV treatment faced higher mortality, while IL-6 inhibitors showed a protective effect.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- Early COVID-19 pandemic disproportionately affected New York City.
- People living with HIV (PLWH) represent a vulnerable population with potential comorbidities.
- Understanding COVID-19 outcomes in PLWH is crucial for targeted healthcare strategies.
Purpose of the Study:
- To compare in-hospital morbidity and mortality of COVID-19 patients with and without HIV.
- To identify risk factors for adverse outcomes among hospitalized PLWH with COVID-19.
- To evaluate the impact of specific treatments on COVID-19 outcomes in PLWH.
Main Methods:
- Retrospective cohort study comparing COVID-19 inpatients with and without HIV.
- Analysis of demographic, clinical, and treatment data.
- Statistical comparison of in-hospital mortality, ICU admission, and ventilator use.
Main Results:
- No significant difference in ventilator use, ICU admission, or in-hospital mortality between PLWH and HIV-negative patients.
- PLWH were younger, with higher prevalence of male sex, Black race, malignancies, and chronic liver/renal disease.
- Among PLWH, viral unsuppression, low CD4% (<14), and not being on HIV treatment were associated with higher mortality.
- IL-6 inhibitors were associated with lower mortality in PLWH.
- Certain medications (antifungals, hydroxychloroquine, azithromycin, steroids, vasopressors) were linked to higher mortality in PLWH.
Conclusions:
- Hospitalized COVID-19 patients with HIV do not experience worse outcomes than the general population.
- Specific subgroups of PLWH, including those with low CD4 counts or off HIV treatment, are at increased risk.
- IL-6 inhibitors may improve outcomes for PLWH with COVID-19.
- Further research is needed to clarify the role of various medications in COVID-19 outcomes for PLWH.
Abstract:
COVID-19 in-hospital morbidity and mortality in people living with HIV (PLWH) were compared to HIV-negative COVID-19 patients within a New York City metropolitan health system, the hardest hit region in the United States early in the pandemic. A total of 10,202 inpatients were diagnosed with COVID-19, of which 99 were PLWH. PLWH were younger (58.3 years (SD = 12.42) versus 64.32 years (SD = 16.77), p < 0.001) and had a higher prevalence of men (73.7% versus 57.9%, p = 0.002) and Blacks (43.4% versus 21.7%, p < 0.001) than the HIV-negative population. PLWH had a higher prevalence of malignancies (18% versus 7%, p = < 0.001), chronic liver disease (12% versus 3%, p < 0.001), and end-stage renal disease (11% versus 4%, p = 0.007). Use of a ventilator, admission to the ICU, and in-hospital mortality were not different. Of the 99 PLWH, 12 were virally unsuppressed and 9 had CD4% < 14. Two of the 12 virally unsuppressed patients and 4/9 patients with CD4% < 14 died. Ninety-one of the 99 PLWH were on treatment for HIV, and 5 of the 8 not on treatment died. Among PLWH with prior values, absolute CD4 count decreased an average of 192 cells/mm3 at the time of COVID-19 diagnosis (p < 0.001). Hospitalized patients with HIV and COVID-19 coinfection did not have worse outcomes than the general population. Among PLWH, those with CD4%<14 or not on treatment for HIV had higher mortality rates. Those PLWH who received IL-6 inhibitors had lower mortality rates. PLWH given antifungal medications, hydroxychloroquine, antibiotics (including azithromycin), steroids, and vasopressors had higher mortality rates.
Related Concept Videos
Sexually Transmitted Infections
Retrovirus Life Cycles
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

